Video

ASCRS Live: Laser scleral microporation from Ace Vision Group

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

Mitchell Jackson, MD, discussed laser scleral microporation from Ace Vision Group at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Mitchell Jackson, MD:

Hi, I'm Dr. Mitchell Jackson. I'm founder and CEO of Jacksoneye in Lake Villa, Illinois, and today we're going to talk about laser scleral microporation from Ace Vision Group. This technology is a treatment for the aging eye. We actually put micropores in the sclera in four quadrants and we do this at the early presbyopia age between like 40 and 55 [if] you haven't developed a cataract yet. We're trying to prevent the aging process from happening. And if it's already happened, we're trying to get the vision recovered from the aging process. You no longer have to wear reading glasses, at least for your cell phone, iPad, laptop, or most of our activities of daily living at near vision.

The difference with this technology versus others... The data so far out to 2 years in our OUS data shows that it's stable out to 2 years to a level that equates to what we see with our premium advanced IOLs, at least J3 or better for intermediate and near vision and with no loss of distance vision uncorrected.

The great thing about [it is] it's extraocular. It's not intraocular. So you have none of the risks of an intracular procedure. It's done on the sclera, not done in the eye or on the cornea or in the visual axis. There's no potential sight-threatening adverse events such as glare or halo because we're not in the visual axis. We're outside the visual axis. It doesn't affect anything for future cataract surgery, because eventually you're gonna get a cataract and need cataract surgery, so it will not affect keratometry or biometry. IOL calculations will not have to be altered if you do this procedure at the early presbyopia age. So those are the big differences. Stay tuned for laser scleral microporation.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.